Market open
$
11.55
Change
+0.16 +1.40%
Volume
Volume 913,717
Jan 30, 2023, 12:07 p.m.
Real time quotes
Previous close
$ 11.39
$ 11.55
Change
+0.16 +1.40%
Day low
Day high
$11.52
$12.48

52 week low
52 week high
$5.63
$20.60

Market cap
$2.14B
Average volume
1.06M
P/E ratio
N/A
Rev. per Employee
$121,257
EPS
-0.68
Dividend
N/A
Div yield
N/A
Ex dividend date
N/A
MarketWatch News on CVAC
-
Super Micro, CureVac, Schwab, Roblox, and More Market Movers
- Barron's Online
-
CureVac upgraded to buy from neutral at UBS
- Tomi Kilgore
-
CureVac Stock Has Nearly Doubled in Three Days. Here's Why.
- Barron's Online
-
CureVac shares surge after preliminary data on COVID-19 and flu shots
- Steve Goldstein
-
Moderna Sues Pfizer, BioNTech for mRNA Patent Infringement
- Barron's Online
-
Merck Jumps Into a $3.7 Billion mRNA Collaboration
- Barron's Online
-
Market Ends Flat on Recession Fears
- Barron's Online
-
CureVac Sues BioNTech Over mRNA Technology
- Barron's Online
-
Data From mRNA Cancer Treatment Look Positive, but Very Early
- Barron's Online
-
CureVac and Glaxo Begin Testing New 'Second Generation' Covid-19 Vaccine
- Barron's Online
- Loading more headlines...
Other News on CVAC
-
CureVac N.V. 2022 Q3 - Results - Earnings Call Presentation
- Seeking Alpha
-
CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
Notable earnings before Wednesday's open
- Seeking Alpha
-
Gates Foundation added LumiraDX, pared Atreca stake in Q3
- Seeking Alpha
-
Moderna Sues Pfizer and BioNTech Over mRNA Patents
- The Wall Street Journal Interactive Edition
-
Health Care falls 2.8% in June, Nutex, CureVac biggest losers
- Seeking Alpha
-
CureVac acquiring Frame Cancer Therapeutics for €32 million
- Seeking Alpha
- Loading more headlines...
Press Releases on CVAC
-
Thursday's ETF with Unusual Volume: IDNA
- MarketNewsVideo.com
- Loading more headlines...
Rates »
National averages from Bankrate.com
National averages from Bankrate.com
National averages from Bankrate.com